148928-15-8

Basic information

• Product Name: FMOC-ISONIPECOTIC ACID
• Synonyms: RARECHEM AR PA 0004;N-ALPHA-(9-FLUORENYLMETHYLOXYCARBONYL)-PIPERIDINE-4-CARBOXYLIC ACID;N-(9-FLUORENYLMETHOXYCARBONYL)-HEXAHYDROISONICOTINIC ACID;N-(9-FLUORENYLMETHOXYCARBONYL)-4-PIPERIDINECARBOXYLIC ACID;N-(9-FLUORENYLMETHYLOXYCARBONYL)-PIPERIDINE-4-CARBOXYLIC ACID;N-(9-FLUORENYLMETHYLOXYCARBONYL)-ISONIPECOTIC ACID;N-ALPHA-FMOC-PIPERIDINE-4-CARBOXYLIC ACID;BUTTPARK 154\50-71
• CAS NO: 148928-15-8
• Molecular Formula: C₂₁H₂₁NO₄
• Molecular Weight: 351.39574
• EINECS: 2017-001-1
• Product Categories: Amino Acids
• Mol File: 148928-15-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: ~190 °C (dec.)
• Boiling Point: 561.624 °C at 760 mmHg
• Flash Point: 293.46 °C
• Appearance: White/Powder
• Density: 1.293
• Vapor Pressure: 1.89E-13mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: 2-8°C
• PKA: 4.54±0.20(Predicted)
• BRN: 7722550
• CAS DataBase Reference: FMOC-ISONIPECOTIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-ISONIPECOTIC ACID(148928-15-8)
• EPA Substance Registry System: FMOC-ISONIPECOTIC ACID(148928-15-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 148928-15-8(Hazardous Substances Data)

Usage

Description

FMOC-ISONIPECOTIC ACID, also known as 9-fluorenylmethoxycarbonyl-isonipecotic acid, is a chemical compound that serves as a valuable building block in the synthesis of various peptides and pharmaceuticals. It is a white powder with unique chemical properties that make it suitable for use in the development of anti-thrombotic agents.

Uses

Used in Pharmaceutical Industry:
FMOC-ISONIPECOTIC ACID is used as a building block for the synthesis of anti-thrombotic peptide libraries. Its incorporation into peptide structures aids in the development of novel therapeutic agents that can help prevent blood clot formation, which is a critical factor in the treatment and management of various cardiovascular diseases.
Additionally, FMOC-ISONIPECOTIC ACID can be utilized in other applications within the pharmaceutical industry, such as the synthesis of other bioactive peptides or as a component in drug delivery systems, due to its versatile chemical properties and reactivity.

InChI:InChI=1/C21H21NO4/c23-20(24)14-9-11-22(12-10-14)21(25)26-13-19-17-7-3-1-5-15(17)16-6-2-4-8-18(16)19/h1-8,14,19H,9-13H2,(H,23,24)

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 5984-56-5 piperidine-4-carboxylic acid hydrochloride 
• 498-94-2 isonipecotic acid 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 

Downstream Products

• 816464-43-4 9H-fluoren-9-ylmethyl 4-[(3-amino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)carbonyl]piperidine-1-carboxylate 
• 816464-44-5 9H-fluoren-9-ylmethyl 4-[(3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)carbonyl]piperidine-1-carboxylate 
• 816464-57-0 3-anilino-7-phenyl-2-(piperidin-4-ylcarbonyl)thieno[2,3-b]pyridin-6(7H)-one 
• 661472-77-1 H-Inp-(D-2Nal)-(D-Trp)(Ψ)-Pim 

Relevant articles and documents

Beyond Basicity: Discovery of Nonbasic DENV-2 Protease Inhibitors with Potent Activity in Cell Culture

The viral serine protease NS2B-NS3 is one of the promising targets for drug discovery against dengue virus and other flaviviruses. The molecular recognition preferences of the protease favor basic, positively charged moieties as substrates and inhibitors, which leads to pharmacokinetic liabilities and off-target interactions with host proteases such as thrombin. We here present the results of efforts that were aimed specifically at the discovery and development of noncharged, small-molecular inhibitors of the flaviviral proteases. A key factor in the discovery of these compounds was a cellular reporter gene assay for the dengue protease, the DENV2proHeLa system. Extensive structure-activity relationship explorations resulted in novel benzamide derivatives with submicromolar activities in viral replication assays (EC50 0.24 μM), selectivity against off-target proteases, and negligible cytotoxicity. This structural class has increased drug-likeness compared to most of the previously published active-site-directed flaviviral protease inhibitors and includes promising candidates for further preclinical development.

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

Diaminopropionic acid derivatives

A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.